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Abstract
Background: A prothrombotic tendency could partially explain the poor prognosis of
patients with coronary heart disease and depression. We hypothesized that cognitive
depressive symptoms are positively associated with the coagulation activation
marker D-dimer throughout the first year after myocardial infarction (MI).
Methods: Patients with acute MI (mean age 60 years, 85% men) were investigated at
hospital admission (n = 190), 3 months (n = 154) and 12 months (n = 106). Random
linear mixed regression models were used to evaluate the relation between cognitive
depressive symptoms, assessed with the Beck depression inventory (BDI), and
changes in plasma D-dimer levels. Demographics, cardiac disease severity, medical
comorbidity, depression history, medication, health behaviors, and stress hormones
were considered for analyses.
Results: The prevalence of clinical depressive symptoms (13-item BDI score ≥ 6) was
13.2% at admission and stable across time. Both continuous (p < .05) and categorical
(p < .010) cognitive depressive symptoms were related to higher D-dimer levels over
time, independent of covariates. Indicating clinical relevance, D-dimer was 73 ng/ml
higher in patients with a BDI score ≥ 6 versus those with a score < 6. There was a
cognitive depressive symptom-by-cortisol interaction (p < .05) with a positive associ-
ation between cognitive depressive symptoms and D-dimer when cortisol levels were
high (p < .010), but not when cortisol levels were low (p > .05). Fluctuations (up and
down) of cognitive depressive symptoms and D-dimer from one investigation to the
next showed also significant associations (p < .05).
Conclusions: Cognitive depressive symptoms were independently associated with
hypercoagulability in patients up to 1 year after MI. Hypothalamic–pituitary–adrenal
axis could potentially modify this effect.
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1 | INTRODUCTION
Psychosocial factors have been associated with an increased risk of cardio-
vascular disease (CVD), independently of and similarly strong as traditional
biological risk factors.1 Depression is arguably the most reliably identified
psychosocial risk factor of incident coronary heart disease (CHD)2 and
poor prognosis after myocardial infarction (MI).3 Moreover, a recent meta-
analysis showed depression to be associated with an increased risk of
major adverse cardiovascular events and all-cause mortality in patients
with CHD who underwent percutaneous coronary intervention.4 The
pooled prevalence of depression among patients with MI is 29%, which is
2.5-fold higher than in the general population.5 Even mild depressive
symptoms may increase mortality risk, indicating a dose–response relation
between depression severity and poor prognosis.6 The mechanisms con-
tributing to adverse cardiovascular outcomes in patents with CHD and
depression are multifactorial and incompletely understood.7
A clotting diathesis, including platelet hyperactivity, is one candi-
date mechanism for atherothrombotic complications in patients with
CHD and depression.7,8 However, the full sequence of events from
acute MI to depression to a procoagulant state and thrombotic out-
comes has not yet been demonstrated.6 To advance this knowledge,
longitudinal investigations with reliable, easy-to-determine global hyp-
ercoagulability markers seem promising. For instance, the fibrin degra-
dation product D-dimer has a plasma half-life of 8 h and indicates
enhanced in vivo fibrin formation and coagulation activation with
therapeutic and prognostic implications for the clinical management
of a number of diseases.9 In experimental and observational studies,
high D-dimer levels were associated with both psychological dis-
tress8,10 and CHD risk, independently of conventional risk factors.11 A
meta-analysis of 18 prospective population-based studies with a total
of 6799 individuals showed an association between D-dimer and inci-
dent CHD risk after 2–19 years of follow-up.12 Studies in patients
referred for coronary intervention showed D-dimer at admission to be
a predictor of all-cause mortality at 6 months13 and after 6.6 years.14
D-dimer measured 2 months after MI was associated with an
increased risk of recurrent coronary events 2 years later.15 In a study
with 7863 patients, D-dimer measured between 5 and 38 months
after an acute coronary syndrome was predictive of an increased risk
of major coronary or cardiovascular events after 6 years and with all-
cause and cardiovascular mortality after 16 years.16
We investigated the hypothesis of a longitudinal association
between greater severity of cognitive depressive symptoms and
higher plasma D-dimer concentration in patients following MI investi-
gated three times over 12 months. Using the Beck depression inven-
tory (BDI), we examined the effect of cognitive depressive symptoms,
because the prognostic impact of somatic symptoms of depression on
cardiovascular outcomes is partially explained by cardiac disease
severity.17 Moreover, compared with cognitive depressive symptoms,
somatic ones such as fatigue show greater overlap with cardiac dis-
ease and may be a direct consequence of the cardiac disease.17 In
addition to adjusting for cardiac health status and inflammation, we
considered demographics, medical comorbidity, health behaviors and
medication as potential confounding variables of D-dimer levels.18
We also adjusted for a history of depression because first-ever
depressive symptoms after cardiac events seem particularly predictive
of adverse outcomes.19 Finally, we examined whether norepinephrine
and cortisol levels partially explain the relation between depressed
mood and D-dimer, as both hormones may link depression with
CHD20 and are associated with hypercoagulability.8
2 | METHODS
This was a secondary analysis of data collected from 190 patients who
participated in the MI-Stress Prevention Intervention (MI-SPRINT) ran-
domized controlled trial (RCT).21 The trial investigated whether one ses-
sion of trauma-focused counseling compared to stress counseling (active
control condition), both delivered within 48 h after hospital admission,
would prevent the development of MI-induced posttraumatic stress at
3 months, which was not the case.22 The ethics committee of the State of
Bern approved the study protocol, which was registered under
ClinicalTrials.gov (NCT01781247). All participants provided written
informed consent.
Inclusion criteria were a minimum age of 18 years, verified acute
ST segment elevation MI (STEMI) or non-STEMI, stable circulatory
conditions and high distress during MI, defined by a minimum score of
5 (range 0–10) for pain intensity and fear of dying and/or helpless-
ness. Exclusion criteria were emergency coronary artery bypass
grafting, severe comorbid diseases, limited orientation, cognitive
impairment, current severe depression (per the cardiologist's medical
history), suicidal ideations in the prior 2 weeks, insufficient German
skills, and participation in another randomized controlled trial.
Of the originally enrolled 190 participants, 154 participated in the
3-month follow-up and 106 in the 12-month follow-up investigation.
Therefore, for this longitudinal observation study, the 190 participants
contributed a total of 450 assessments (mean of 1.6 assessments per
participant) over the entire study period of 12 months. The recruit-
ment procedure and reasons for loss to follow-up have been detailed
elsewhere.22,23 Among others, seven patients had died for various
reasons between hospital discharge and the 3-month follow-up and
39 patients could not be scheduled at 12 months due to lack of
funding. The most frequent reason for missing BDI values at admis-
sion was an immediate transfer of patients back to the referring hospi-
tals before they completed questionnaires. Logistical problems with
blood sampling were the most frequent reasons for missing D-dimer
values at follow-up. Several measures were obtained.
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2.1 | Demographic factors
Information on age and sex was taken from medical records.
2.2 | Indices of cardiac disease severity
These included a history of previous MI, the type of index MI (STEMI or
non-STEMI), left ventricular ejection fraction (LVEF), obtained from
angiographic records, and C-reactive protein (CRP), a marker of the acute
inflammatory response during MI and low-grade systemic chronic inflam-
mation. CRP was measured with an immunoturbidimetric assay
(C-Reactive Protein Gen.3) using the COBAS 8000 c702 module from
Roche Diagnostics at the Institute of Clinical Chemistry, Inselspital, Bern
University Hospital, Switzerland. For clinical routine, the lab provides
CRP values of 20 mg/L and higher as “CRP ≥ 20 mg/L", but no precise
concentration. Based on this, and on the prognostic CVD risk with
increasing CRP levels, CRP values were categorized as follows: <1 mg/L,
1 to ≤3 mg/L, 3 to ≤10 mg/L, 10 to <20 mg/L, and ≥ 20 mg/L.24
2.3 | Comorbidity
We calculated the Charlson comorbidity index which was categorized
by low (index = 1), medium (index =2) or high (index = 3+) 10-year
mortality risk.25
2.4 | Medication
Information on current use of aspirin, other platelet inhibitors
(clopidogrel, ticagrelor, and prasugrel), oral anticoagulants (OAC:
vitamin K antagonists and direct OAC), statins, antidepressants, and
glucocorticoids were collected from medical charts and interviewer-
assessed.
2.5 | Health behaviors
Body mass index (BMI) was calculated based on self-disclosed weight
and height at admission, and on measured weight and height at both
follow-ups. Patients were categorized in current or nonsmokers. Fre-
quency of physical activity per week “that makes you sweat” was cat-
egorized as none, 1–2 or 3–7. Alcohol consumption was
categorized as none, moderate or heavy; the latter based on the num-
ber of standard drinks per week (>21 for men, >14 for women).
2.6 | Cognitive depressive symptoms and history
of depression
We assessed cognitive depressive symptoms with the 13-item self-
rated cognitive depressive symptom subscale of the BDI.26 Each item
is scored with a value between 0 and 3, referring to the severity of
the depressive symptom. The scale yields a total score between 0 and
39. The German version of the 13-item short form of the BDI is a reli-
able tool to assess depressive symptoms in patients with CHD and a
score ≥ 6 was shown to identify clinically significant depressive symp-
toms with a sensitivity of 91.7%.27 In our sample, Cronbach's α was
0.71 at admission, 0.82 at 3-months and 0.74 at 12-months, indicating
acceptable internal consistency for the scale. For information on a
previous episode of depression, patients were asked, “Have you ever
had a depression in your life? (Yes/no)”.
2.7 | Stress hormones
Norepinephrine was quantified by high-pressure liquid chromatogra-
phy in ethylendiamintetraacetic acid (EDTA) plasma using electro-
chemical detection28 at the Laboratory for Stress Monitoring,
Gottingen, Germany (inter- and intra-assay coefficients of variation
[CV] <10%). Serum cortisol was determined with an electro-
chemiluminescence immunoassay on a Cobas analyzer (Roche Diag-
nostics, Switzerland) at the Institute of Clinical Chemistry, Inselspital,
Bern University Hospital, Switzerland.
2.8 | Fibrin D-dimer
Following a strict in-house protocol to ensure adequate preanalytical
conditions, D-dimer was measured in citrate plasma at the accredited
Hemostasis Laboratory, Inselspital, Bern University Hospital,
Switzerland. Determination was with a quantitative sandwich enzyme
immunoassay (VIDAS-D-Dimer, bioMérieux, Geneva, Switzerland) or
with a particle-based immunoturbidimetric assay (Innovance®
D-Dimer; Siemens AG, Munich, Germany). Within-run CV were
2%–12% and day-to-day CV were 2%–3% for both assays. The
Vidas® assay is the most clinically validated D-dimer measurement
technique and thus considered the reference commercial quantitative
immunoassay.9 However, the Innovance® assay has equally good
analytical performance as the Vidas® assay9 and D-dimer values are
highly correlated (r = 0.95) when determined with these two methods.29
Data were analyzed with SPSS 26.0 for Windows (SPSS Inc.,
Chicago, IL) and two-tailed significance at p < .05. We conducted a
linear mixed (random effects) regression analysis to examine the
covariate-adjusted longitudinal relation between cognitive depres-
sive symptoms and plasma D-dimer across three investigations
(hospital admission, 3-month, and 12-month follow-ups). With lin-
ear mixed model regression an intercept and slope of each partici-
pant can be estimated based on the available data for that
individual (i.e., even when some points are missing across the three
investigations), augmented by the data from the entire sample. We
prioritized the continuous BDI score as a predictor variable; how-
ever, to test for a relation between clinically significant depressive
symptoms and D-dimer levels, we also used a categorical BDI score
of ≥6 versus <6.27 Due to a nonnormal distribution, D-dimer values
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were log (base 10) transformed prior to analysis. Three outliers with
a log-transformed D-dimer value greater than three SDs above the
sample mean were deleted.
The covariates listed below were considered on an a priori basis
as potential confounders of D-dimer levels.16,18 We first modeled
univariable associations of cognitive depressive symptoms and each
covariate with D-dimer levels over time. Akaike's information criterion
(AIC) showed a better model fit with “time” (i.e., the number of
assessments over time) as a log (base 10) transformed variable
(AIC = 48.9) instead of a linear variable (AIC = 54.2). This may reflect
the fact that D-dimer rises during acute MI, such that a more rapid
decline is expected earlier rather than later after MI.
As a next step, we calculated two multivariable models for cogni-
tive depressive symptoms with covariates entered into models as
fixed effects. In Model 1, these covariates were demographics
(i.e., age, sex); indices of cardiac disease severity (i.e., index MI, LVEF,
CRP, and previous MI); Charlson comorbidity index, depression
history, medication use (i.e., aspirin, platelet inhibitors, OAC, statins,
antidepressants, and glucocorticoids) and health behaviors (i.e., BMI,
smoking, alcohol consumption, and physical activity). In Model 2, we
additionally entered stress hormones (i.e., norepinephrine and cortisol
levels). Like depressive symptoms, CRP, medication use, health behav-
iors, and stress hormones were all entered as time varying. Random
intercepts were modeled for participants.
Model 2 allowed us to test the extent to which stress hormones
potentially mediate the link between cognitive depressive symptoms
and D-dimer. In statistical terms, this would be the case if a significant
relation between cognitive depressive symptoms and D-dimers was
no longer significant after stress hormones were added to the equa-
tion. Potential effect modification by stress hormones was further
tested by entering an interaction term between cognitive depressive
symptoms and each stress hormone into Model 2. For significant
interactions, we applied the Holmbeck method30 to test whether the
level of stress hormones (+1 SD vs. 1 SD from the mean) would
moderate the relation between cognitive depressive symptoms and
D-dimer levels.
We computed both between- and within-participants effects of
cognitive depressive symptoms on D-dimer. The between-participants
analysis tests whether patients who are generally (i.e., over the entire
study period) higher in cognitive depressive symptoms are also those
showing higher D-dimer levels over the entire study period. The within-
participants analysis tests whether, at individual investigations, a patient
who reports a higher level of cognitive depressive symptoms also shows
higher D-dimer, suggesting an association between fluctuations (up or
down) in cognitive depressive symptoms and D-dimer. To obtain
within-participants effects, each patient's personal mean value across
time was subtracted from each of his or her individual observation.
3 | RESULTS
Table 1 shows the characteristics of the study participants at hospital
admission and for the two follow-up investigations. The
190 participants who were included into the study contributed
450 assessments across the three investigations (see legend to
Table 1 for the percentage of complete values for each variable). At
admission, mean age of participants was 60 years. The majority were
men and had rather low comorbidity. Whereas 27.9% of patients
reported a history of depressive illness, 13.2% met the cutoff for clini-
cally significant depressive symptoms (BDI score ≥ 6) and 8.4% took
antidepressants. The participants who provided assessments at
follow-up had similar time-invariant characteristics to those who con-
tributed assessments at admission, suggesting that there was little
concern for an attrition bias. In terms of time-variant variables, there
was a drop in absolute values of CRP, cortisol, and D-dimer levels on
the one hand, and an increase in more favorable health behaviors with
less smoking and greater physical activity on the other. Mean cogni-
tive depressive symptom scores and the prevalence of clinically signif-
icant depressive symptoms were similar across the three
investigations; yet, the frequency of antidepressant use had almost
doubled at 12 months compared to admission. Except for a decrease
in the use of platelet inhibitors, the frequency of cardiovascular medi-
cation use changed little over time.
Univariable associations of between-participants effects (Table 2)
showed a significant decrease in D-dimer over time (i.e., a significant
negative estimate for “time”). Greater cognitive depressive symptom
scores, both continuous and categorical, were significantly related to
higher D-dimer levels for the entire study period of 12 months. There
were additional significant univariable relations with D-dimer for
higher age, lower LVEF, higher CRP, previous MI, greater comorbidity,
glucocorticoid use, less physical activity, higher norepinephrine, and
cortisol levels.
The significance of a positive association of both continuous and
categorical cognitive depressive symptoms with D-dimer levels was
maintained with adjustment for time, demographic factors, indices of
cardiac disease severity, comorbidity, depression history, medication
use, health behaviors, and stress hormones (Table 3, Model 1). The
results from the fully adjusted Model 2 in Table 3 suggested that
stress hormones did not significantly mediate the longitudinal relation
between cognitive depressive symptoms and D-dimer. In addition to
cognitive depressive symptoms, higher age, lower LVEF and higher
CRP were also independently related to higher D-dimer; OAC use
showed an independent association with lower D-dimer. In Model
2, patients with clinically significant depressive symptoms (categorical
BDI score ≥ 6) had a (antilog) 73 ng/ml higher D-dimer level than
those without (BDI score < 6) when all other variables were held con-
stant (303 ng/ml vs. 230 ng/ml).
Univariable analysis of within-participants effects (Table 2)
showed that an increase in the continuous cognitive depressive symp-
tom score and in cortisol levels, but not in norepinephrine levels, were
significantly associated with an increase in D-dimer levels from one
investigation to the next. In the multivariable analysis (Table 4), the
significant relation between cognitive depressive symptoms and D-
dimer was maintained with adjustment for time, demographic factors,
indices of cardiac disease severity, comorbidity, depression history,
medication use and health behaviors (Table 4, Model 1) and,
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Age, years, M (SD) 59.9 (11.2) 58.7 (10.9) 59.7 (9.9)
Sex, male, n (%) 157 (82.6) 130 (84.4) 88 (83.0)
ST-elevation myocardial infarction, n (%) 134 (70.5) 110 (71.4) 74 (69.8)
Left ventricular ejection fraction, %, M
(SD)
47.6 (11.8) 47.6 (11.8) 48.3 (12.1)
Previous myocardial infarction, n, (%) 20 (10.5) 13 (8.4) 9 (8.5)
Charlson comorbidity index
Low risk, n (%) 103 (54.2) 88 (57.1) 54 (50.9)
Medium risk, n (%) 49 (25.8 39 (25.3) 30 (28.3)
High risk, n (%) 38 (20.0) 27 (17.5) 22 (20.8)
Depression history, n (%) 53 (27.9) 45 (29.2) 27 (25.5)
Time-variant
C-reactive protein
<1 mg/L, n (%) 6 (3.2) 62 (40.3) 43 (40.6)
1 to ≤3 mg/L, n (%) 14 (7.4) 41 (26.6) 26 (24.5)
3 to ≤10 mg/L, n (%) 35 (18.4) 13 (8.4) 12 (11.3)
10 to <20 mg/L, n (%) 32 (16.8) 3 (1.9) 0 (0)
≥20 mg/L, n (%) 86 (45.3) 1 (0.6) 1 (0.9)
Aspirin, n (%) 185 (97.4) 141 (91.6) 96 (90.6)
Platelet inhibitors, n (%) 180 (94.7) 133 (86.4) 70 (66.7)
Oral anticoagulants, n (%) 21 (11.1) 21 (13.6) 12 (11.3)
Statins, n (%) 183 (96.3) 146 (94.8) 100 (94.3)
Antidepressants, n (%) 16 (8.4) 15 (9.7) 16 (15.1)
Glucocorticoids, n (%) 8 (4.2) 3 (1.9) 2 (1.9)
Body mass index, kg/m2, M (SD) 28.0 (4.9) 27.4 (4.8) 27.8 (4.9)
Current smoker, n (%) 83 (43.7) 20 (13.0) 13 (12.3)
Alcohol consumption
None 33 (17.4) 37 (24.0) 23 (21.7)
Mild-to-moderate 144 (75.8) 108 (70.1) 78 (73.6)
Heavy 10 (5.3) 9 (5.8) 5 (4.7)
Physical activity
None 88 (46.3) 38 (24.7) 29 (27.4)
1–2/week 50 (26.3) 20 (13.0) 28 (26.4)
3–7/week 49 (25.8) 96 (62.3) 49 (46.2)
Norepinephrine, pg/ml, M (SD) 565 (360) 667 (313) 662 (275)
Cortisol, nmol/L, M (SD) 517 (206) 347 (120) 377 (117)
D-dimer, ng/ml, M (SD) 643 (510) 471 (391) 506 (442)
Depressive symptoms, score, M (SD) 2.75 (2.83) 2.46 (3.18) 2.35 (2.65)
Depressive symptoms, score ≥ 6, n (%) 25 (13.2) 18 (11.7) 13 (12.3)
Note: Due to missing data, some percent values do not add up to 100%. Data for the time-invariant variables were complete in 100% for age, sex and the
Charlson comorbidity index; in 99.1% for index myocardial infarction; in 98.4% for previous myocardial infarction and depression history; and in 96.9% for
left ventricular ejection fraction. Data for the time-variant variables were complete in 99.6 for smoking status; in 99.3% for aspirin, platelet inhibitors, oral
anticoagulants, statins, alcohol consumption, and physical activity; in 99.1% for antidepressants and glucocorticoids; in 96.7% for body mass index; in
88.4% for cognitive depressive symptoms; in 83.3% for D-dimer; in 83.3% for C-reactive protein; in 82.7% for cortisol; and in 76.7% for noradrenalin.
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additionally, for within-participants changes in stress hormones
(Table 4, Model 2). However, the relation between cortisol and D-
dimer was no longer significant after adjustment for covariates. The
results from Model 2 in Table 4 suggest that changes in stress hor-
mones from one investigation to the next did not mediate the associa-
tion between fluctuations in cognitive depressive symptoms and D-
dimer levels.
Next, we tested whether stress hormones would be effect mod-
erators of between-participants effects. There was a significant cogni-
tive depressive symptom score-by-cortisol interaction for D-dimer
levels over time, adjusting for time, demographics, indices of cardiac
disease severity, comorbidity, depression history, medication use,
health behaviors, norepinephrine levels, and main effects of cortisol
levels and cognitive depressive symptoms (estimate [SE] = 0.006
(0.003), p < .05). Post hoc analysis revealed that cognitive depressive
symptoms were associated with D-dimer when cortisol levels were
high (estimate [SE] = 0.022 (0.007), p < .010), but not significantly so
when cortisol levels were low (estimate [SE] <0.001 (0.008)). No sig-
nificant interactions emerged between categorical depressive symp-
toms and cortisol and between cognitive depressive symptom scores,
both continuous and categorical, and norepinephrine levels.
In the within-participants analysis, there was no significant inter-
action between continuous cognitive depressive symptoms and both
norepinephrine and cortisol levels, adjusting for time, demographics,
indices of cardiac disease severity, comorbidity, depression history,
medication use, health behaviors, and main effects of both the other
stress hormone and cognitive depressive symptoms.
4 | DISCUSSION
We found a significant longitudinal relation between cognitive depres-
sive symptoms and plasma D-dimer levels in patients followed for up
to 12 months after acute MI. Patients who endorsed more severe
TABLE 2 Univariable between- and
within-participants effects for relations
with D-dimer levels across the entire
study period of 12 months
Parameter Estimate SE Counts (n)
Intercept 2.660*** 0.019 372
Time 0.273*** 0.054 372
Age, years 0.042*** 0.008 372
Sex, male 0.016 0.052 372
ST-elevation MI 0.019 0.043 368
Left ventricular ejection fraction, % 0.024** 0.008 360
C-reactive protein 0.055*** 0.007 369
Previous myocardial infarction 0.160* 0.066 366
Comorbidity index 0.106*** 0.023 372
Depression history 0.030 0.045 366
Aspirin 0.035 0.058 370
Platelet inhibitors 0.007 0.043 370
Oral anticoagulants 0.003 0.050 370
Statins 0.088 0.068 370
Antidepressants 0.054 0.051 370
Glucocorticoids 0.188* 0.095 370
Body mass index, kg/m2 0.024 0.020 371
Current smoker 0.053 0.031 370
Alcohol consumption 0.008 0.026 369
Physical activity 0.062*** 0.015 369
Norepinephrine (between), pg/ml 0.012* 0.005 335
Cortisol (between), nmol/L 0.039*** 0.007 365
Depressive symptoms (between), continuous 0.013* 0.005 337
Depressive symptoms (between), categorical 0.108** 0.040 337
Norepinephrine (within), pg/ml 0.001 0.007 335
Cortisol (within), nmol/L 0.032*** 0.009 365
Depressive symptoms (within), continuous 0.020** 0.007 337
Note: ***p < .001; **p < .010; *p < .05 denotes the significance level. Age, left ventricular ejection
fraction, and body mass index were entered in 5-unit steps; norepinephrine and cortisol were entered in
100-unit steps; cognitive depressive symptom score was entered in 1-unit steps. Time and D-dimer were
entered as log (base 10) transformed values. All other parameters were entered as categorical variables
(see Table 1 for these categories).
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cognitive depressive symptoms had greater blood coagulability in the
first year following MI than patients with less depressed mood. This
relation was independent of a range of factors potentially con-
founding this relation. In fact, several covariates showed expected
associations with D-dimer levels in univariable and multivariable
models. Significant independent associations with elevated D-dimer
emerged for older age, higher CRP and lower LVEF, whereas OAC use
was associated with lower D-dimer.18 Moreover, changes in depres-
sive mood severity and plasma D-dimer concentration from one inves-
tigation to the next were significantly related to each other,
independent of covariates.
These findings further substantiate the literature on a pro-
thrombotic tendency as a potential mechanism underlying the
increased risk of atherothrombotic CVD events in patients with
depression. Previous research assessed hypercoagulability in terms of
different hemostasis measures, including platelet hyperactivity,
clotting factors, global hypercoagulability markers and impaired fibri-
nolysis.7,8 However, unlike our study, previous studies have rarely
been performed in depressed patients with established CHD, were
cross-sectional or assessed hemostasis factors at only one point in
time.8 To illustrate this, in two previous studies of patients with stable
CHD, D-dimer level was unrelated to depressive mood.31,32 However,
both studies measured D-dimer only once, and one study did not take
potentially confounding variables into account.31
Our findings may help to understand why patients with treatment
resistant depression,33 incident depression19 and more severe depres-
sion34 show a particularly poor prognosis following MI. As a constant
severity of cognitive depressive mood over 1 year was related to
D-dimer, hypercoagulability might prevail in the first year after MI in
patients who experience no reduction in cognitive depressive symptoms
(with or without treatment). Moreover, as a history of depression was
not associated with D-dimer levels over time, our findings substantiate
the potential importance of incident cognitive depressive symptoms for
hypercoagulability following MI. In addition, the observed gradual rela-
tion between cognitive depressive symptoms and D-dimer suggests that
even minimal symptoms of depression may relate to hypercoagulability.
TABLE 3 Multivariable between-
participants effects for the relations
between cognitive depressive symptoms
and D-dimer levels across the entire
study period of 12 months
Parameter
Model 1 Model 2
Estimate SE Estimate SE
Intercept 2.331*** 0.217 2.337*** 0.228
Time 0.012 0.083 0.034 0.091
Age, years 0.033*** 0.009 0.027** 0.009
Sex, male 0.018 0.050 0.006 0.052
ST-elevation myocardial infarction 0.009 0.046 0.004 0.046
Left ventricular ejection fraction, % 0.021* 0.009 0.021* 0.009
C-reactive protein 0.049*** 0.011 0.052*** 0.013
Previous MI 0.016 0.067 0.044 0.070
Comorbidity index 0.050 0.026 0.048 0.025
Depression history 0.019 0.045 0.014 0.046
Aspirin 0.107* 0.053 0.099 0.057
Platelet inhibitors 0.001 0.042 0.002 0.044
Oral anticoagulants 0.149** 0.051 0.132* 0.054
Statins 0.075 0.061 0.119 0.063
Antidepressants 0.038 0.048 0.078 0.052
Glucocorticoids 0.061 0.085 0.135 0.094
Body mass index, kg/m2 0.017 0.019 0.032 0.020
Current smoker 0.006 0.033 0.026 0.037
Alcohol consumption 0.012 0.023 0.005 0.024
Physical activity 0.012 0.015 0.007 0.016
Norepinephrine, pg/ml 0.008 0.005
Cortisol, nmol/L 0.014 0.009
Depressive symptoms, continuous 0.011* 0.005 0.012* 0.005
Depressive symptoms, categorical 0.094* 0.037 0.119** 0.041
Note: ***p < .001; **p < .010; *p < .05 denotes the significance level. Age, left ventricular ejection
fraction, and body mass index were entered in 5-unit steps; norepinephrine and cortisol were entered in
100-unit steps; continuous cognitive depressive symptom score was entered in 1-unit steps. Time and D-
dimer were entered as log (base 10) transformed values. All other parameters were entered as categorical
variables (see Table 1 for these categories). The results for the categorical cognitive depressive symptom
score (score ≥ 6) are shown without estimates of the other variables in the models.
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Our findings may have clinical implications. Higher D-dimer dur-
ing admission for MI, and when assessed following MI at similar time
points as in our study, has been shown to predict recurrent cardiac
events.13–16 The 13% of our patients who reached the cut-off for clin-
ically significant depressive symptoms had a 73 ng/ml higher D-dimer
concentration than those without clinically significant symptoms. This
difference is about half that between the top (>273 ng/ml) and bot-
tom (≤112 ng/ml) quartiles of D-dimer in a large prospective study of
patients with acute coronary syndromes.16 Compared to patients in
the bottom quartile of D-dimer levels, those in the top quartile
showed a 1.5-fold greater risk of a major coronary event after 6 years
and of cardiovascular mortality after 16 years.16 Moreover, as fluctua-
tions in cognitive depressive symptoms and D-dimer showed signifi-
cant associations, successful treatment of depression could perhaps
reduce D-dimer and cardiac risk within only a few months. This
hypothesis deserves to be tested in future studies. To concur, a previ-
ous study found decreased platelet activation after 6 months of effec-
tive depression treatment with psychotherapy or antidepressants in
patients with depressed mood and a history of CVD.35 However, as
the design of our study does not allow for causal inferences, lowering
D-dimer levels, for example, by improving cardiac function, could also
lower depressive mood. Such a bi-directional view is supported by an
increasing literature showing that hemostasis factors are also
expressed in the brain and that they may influence brain function and
mood.7,36,37
We found some evidence for effect modification for cortisol
levels. Specifically, there was a significant relation between cognitive
depressive symptoms and D-dimer when cortisol was high for the
entire study period, but not when cortisol was low. This observation
might reflect cumulative allostatic load referring to the biological and
mental burden emerging from adaptation to chronic stress and life
events.38 Within an allostatic framework, depression might be related
to hypercoagulability especially when depressed mood occurs after a
stressful experience, which an acute MI is in 70% of cases,39 leading
to a sustained activation of the hypothalamic–pituitary–adrenal axis.
In contrast, cortisol was not a moderator of associations between cog-
nitive depressive symptoms and D-dimer from one investigation to
the next. The reason for this discrepancy could be different dynamics
of the relations between cognitive depressive symptoms, cortisol, and
D-dimer over 12 months versus a few months. Another explanation
TABLE 4 Multivariable within-
participants effects for the relations
between cognitive depressive symptoms
and D-dimer levels across the entire
study period of 12 months
Parameter
Model 1 Model 2
Estimate SE Estimate SE
Intercept 2.395*** 0.214 2.481*** 0.222
Time 0.005 0.084 0.008 0.092
Age, years 0.031*** 0.009 0.029** 0.009
Sex, male 0.019 0.050 0.002 0.052
ST-elevation myocardial infarction 0.019 0.046 0.017 0.046
Left ventricular ejection fraction, % 0.021* 0.009 0.023* 0.009
C-reactive protein 0.050*** 0.011 0.053*** 0.013
Previous myocardial infarction 0.018 0.067 0.063 0.069
Comorbidity 0.049 0.025 0.046 0.025
Depression history 0.040 0.043 0.035 0.044
Aspirin 0.104 0.053 0.089 0.057
Platelet inhibitors 0.001 0.042 0.004 0.044
Oral anticoagulants 0.150** 0.052 0.137* 0.054
Statins 0.073 0.061 0.112 0.064
Antidepressants 0.051 0.048 0.085 0.051
Glucocorticoids 0.070 0.085 0.140 0.094
Body mass index, kg/m2 0.020 0.019 0.036 0.020
Current smoker 0.004 0.033 0.023 0.037
Alcohol consumption 0.016 0.023 0.014 0.024
Physical activity 0.010 0.016 0.007 0.017
Norepinephrine (within), pg/ml 0.008 0.006
Cortisol (within), nmol/L 0.017 0.011
Depressive symptoms (within), continuous 0.015* 0.006 0.017* 0.007
Note: ***p < .001; **p < .010; *p < .05 denotes the significance level. Age, left ventricular ejection
fraction, and body mass index were entered in 5-unit steps; norepinephrine and cortisol were entered in
100-unit steps; the continuous depressive symptom score was entered in 1-unit steps. Time and D-dimer
were entered as log (base 10) transformed values. All other parameters were entered as categorical
variables (see Table 1 for these categories).
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could be single determinations of norepinephrine and cortisol in
blood, which provide less reliable measures than 24-hour urine collec-
tion. This methodological shortcoming may also explain why norepi-
nephrine did not modify the relation between cognitive depressive
mood and D-dimer and why stress hormones did not mediate this
relation.
The longitudinal design with up to three repetitive investigations
and rigorous control of time varying and of potentially confounding
variables of D-dimer values are notable strengths of our study, which
also has several limitations worth mentioning. We included patients
with high distress during MI who participated in an RCT aimed at
preventing psychological sequelae of MI. Although additional adjust-
ment for the intervention group did not change the results (not
shown), our findings should not be generalized to the population of
patients with acute MI at large. In addition, women were underrepre-
sented in our sample and medical comorbidity was rather low. Venous
thromboembolism was not an exclusion criterion, and we could not
exclude the possibility that D-dimer levels were influenced by inter-
current venous thromboembolism during follow-up, which we did not
systematically assess. The item to assess depression history did
not ask for a health professional diagnosis of depression and cognitive
depressive symptoms following MI were self-rated. Moreover, for the
RCT, we excluded patients with a current severe depressive illness
based on clinical judgment. This likely resulted in underrepresentation
of patients in the upper range of depressive symptom severity.
Whereas the pooled prevalence of depression is 29% in patients with
MI,5 only 13% met the cut-off for clinically significant cognitive
depressive symptoms in our study; however, the prevalence was simi-
lar to other studies when based on cognitive depressive symptoms.40
Due to low funding, 39 patients could not be assessed at 12 months.
Taken together, we showed a longitudinal and independent asso-
ciation between cognitive depressive symptoms and plasma D-dimer
levels in patients followed up to 1 year after acute MI. The main
finding of our study is consistent with the notion of a prothrombotic
tendency in patients with CHD, which can be partially explained by
depressed mood. The extent to which hypercoagulability accounts for
the increased risk of recurrent cardiac events and poor prognosis in
patients with CHD and depression remains to be studied.
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